Blockade of FGFR signaling using both a pan-FGFR small chemical inhibitor and a FGFR4-specific blocking antibody inhibited the concentric hypertrophy associated with diabetic cardiomyopathy in mice. Here, FGFR4 is linked to diabetic cardiomyopathy.